NGNE

Neurogene Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$23.9

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30

Non-compliant assets / Total market cap %16 / %30

Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

Website

Analysis (Turkish): NGNE Hissesi Caiz mi, Helal mi? Neurogene Inc. Katılım Analizi